Kenes Akilzhanov

Dr. Kenes Akilzhanov

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
SRSaule Rakhimova
Saule Rakhimova
UKUlan Kozhamkulov
Ulan Kozhamkulov
GAGulbanu A. Akilzhanova
Gulbanu A. Akilzhanova
GKGalina K. Kaussova
Galina K. Kaussova
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
The left ventricular assist device (LVAD) is one of the alternative treatments for heart failure (HF) patients. However, LVAD support is followed by thrombosis, and bleeding complications which are caused by high non-physiologic shear stress and antithrombotic/anticoagulant therapy. A high risk of complications occurs in the presence of the genotype polymorphisms which are involved in the coagulation system, hemostasis function and in the metabolism of the therapy. The aim of the study was to investigate the influence of single-nucleotide polymorphisms (SNP) in HF patients with LVAD complications. We analyzed 21 SNPs in HF patients (n = 98) with/without complications, and healthy controls (n = 95). SNPs rs9934438; rs9923231 in VKORC1, rs5918 in ITGB3 and rs2070959 in UGT1A6 demonstrated significant association with HF patients’ complications (OR (95% CI): 3.96 (1.42–11.02), p = 0.0057), (OR (95% CI): 3.55 (1.28–9.86), p = 0.011), (OR (95% CI): 5.37 (1.79–16.16), p = 0.0056) and OR (95% CI): 4.40 (1.06–18.20), p = 0.044]. Genotype polymorphisms could help to predict complications at pre- and post-LVAD implantation period, which will reduce mortality rate. Our research showed that patients can receive treatment with warfarin and aspirin with a personalized dosage and LVAD complications can be predicted by reference to their genotype polymorphisms in VKORC1, ITGB3 and UGT1A6 genes.

22 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Madina ZhalbinovaMadina Zhalbinova
Madina Zhalbinova
SRSaule Rakhimova
Saule Rakhimova
UKUlan Kozhamkulov
Ulan Kozhamkulov
GAGulbanu A. Akilzhanova
Gulbanu A. Akilzhanova
ACAssel A. Chinybayeva
Assel A. Chinybayeva
AAAinur Rakhmetulovna Akilzhanova
Ainur Rakhmetulovna Akilzhanova
Left ventricular assist device (LVAD) implantation is one of the mechanical circulatory support (MCS) treatments for advanced heart failure (HF) patients. MCS has emerged as a lifesaving therapy that improves patients’ quality of life. However, MCS remains limited by a paradoxical coagulopathy accompanied by thrombosis and bleeding. The mechanisms of MCS thrombosis are increasingly being defined, but MCS-related bleeding, which is related to shear-mediated alteration of platelet function, remains poorly understood. Complications might develop due to the high non-physiological shear stress in the device and as a consequence of individual variability in response to the antithrombotic therapy. Thromboelastography (TEG) and genotyping of gene polymorphisms that are involved in the coagulation cascade and in the metabolism of the antithrombotic therapy might be valuable sources of information for the reduction of complication development. The aim of the study was to identify genetic factors related to the development of device complications according to the implanted LVAD type. We compared the clinical and genetic data of HF patients (n = 98) with/without complications with three types of implanted devices: HeartWare HVAD (HW), HeartMate II (HMII), and HeartMate 3 (HM3). rs9923231 in VKORC1 (95%CI −6.28–0.22, p = 0.04) and rs5918 in ITGB3 genes (95%CI 0.003–4.36, p = 0.05) showed significant association with the TEG coagulation index parameter, which identified hyper- and hypo-coagulation states. The wild genotype of rs5918 in the ITGB3 gene prevailed in patients implanted with HM3 devices, which developed fewer complications than with HMII (p = 0.04). Individual genetic information could be useful in the management of patients with HF and the implantation of MCS to reduce the development of complications.

11 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
AGAidana Gabdulkayum
Aidana Gabdulkayum
SASaya Amangeldikyzy
Saya Amangeldikyzy
AYAdil Yerezhepov
Adil Yerezhepov
SKSayipzhamal Khassanova
Sayipzhamal Khassanova
KAKenes Akilzhanov
Kenes Akilzhanov
DYDauren Yerezhepov
Dauren Yerezhepov
Background/Objectives: We aimed to investigate the association between VDR gene variants and vitamin D levels in elite male power athletes of Kazakhstan. Methods: We recruited 92 elite male power athletes of Kazakhstan. Concentrations of serum 25(OH)D were measured with the Access 25(OH) Vitamin D Total Assay on the Unicel Dxl 800 Access Immunoassay System. Gene polymorphisms were determined by a real-time polymerase chain reaction (RT-PCR) allelic discrimination assay using TaqMan™ probes. Results: Vitamin D insufficiency was registered in 63% of athletes. Age (χ2 = 6.83, p < 0.01), BMI (χ2 = 6.83, p < 0.01), and sport experience (χ2 = 4.44, p < 0.04) showed a statistically significant association with vitamin D insufficiency and deficiency (age, χ2 = 7.93, p < 0.01; BMI, χ2 = 5.11, p < 0.03; sport experience, χ2 = 6.19, p = 0.01). The A/A genotype of the VDR FokI polymorphism (rs2228570) showed a strong correlation with vitamin D insufficiency (G/G-G/A vs. A/A, OR = 9.25, 95% CI = 2.01–42.51, p < 0.01) but not deficiency. Conclusions: Our study reveals a significant prevalence of vitamin D insufficiency and deficiency among elite male power athletes of Kazakhstan. Age, BMI, and sport experience are essential factors in developing personalized strategies to address vitamin D insufficiency. The A/A genotype of the VDR FokI polymorphism can be used as a potential biomarker for vitamin D inadequacy in elite male power athletes of Kazakhstan.

28 February 2018 in Наука и здравоохранение
Verified
Journal Article
Open access
KAKenes Akilzhanov
Kenes Akilzhanov
ЖМЖанаспаев М.а.
Жанаспаев М.а.
Актуальность. Остеоартрит (ОА) является актуальной проблемой современной медицины, что подтверждается неуклонным ростом заболеваемости, экономических затрат на лечение и инвалидизации больных.Поскольку коленный сустав является трехкомпонентным, радиологические проявления болезни многочисленны. Пателлофеморальный сустав (ПФС) является одной из наиболее часто поражаемых частей. Хотя OA ПФС наблюдается часто, эта конкретная подгруппа болезней в значительной степени не признана. Недавние исследования показывают, что ПФС не только является важным источником симптомов ОА коленного сустава, но и люди, страдающие ОА ПФС, демонстрируют признаки болезни, отличные от признаков, наблюдаемых при ОА тибиофеморального сустава (ТФС) берцово-бедренного сустава. Это имеет значение для оценки и лечения пациентов с OA ПФС. Цель данного обзораобобщить данные, свидетельствующие о том, почему OA ПФС следует рассматривать как отдельную клиническую единицу и основные методы лечения с использованием консервативных, не фармакологических подходов к лечению. Стратегия поиска. Был проведен литературный поиск в электронных базах данных PubMed/Scopus/MEDLINE, охватывающий последние три десятилетия по ключевым словам: пателлофеморальный сустав, остеоартрит, тибиофеморальный сустав, синдром пателлофеморальной боли. Критерии включения: доступные полнотекстовые статьи по оригинальным исследованиям с 1987 года, диагнозы первичного остеоартрита, критерии исключения: диагноз острого конкурирующего заболевания коленного сустава (разрывы связок, сухожилия), описание отдельных случаев, статьи на других иностранных языках, кроме английского. 83 статьи найдены за период исследования. Результаты. Остеоартрит коленного сустава налагает значительное бремя на страдающих данным состоянием людей и общество в целом. Несмотря на то, что остеоартрит ПФС недостаточно изучен в сравнении с остеоартритом ТФС, ПФС часто вовлечен в процесс заболевания. OA ПФС ассоциируется со значительной болью и инвалидизацией. Клинические результаты OA ПФС могут быть улучшены разработкой новых методов лечения с учетом уникальных биомеханических функций ПФС и специфических нарушений, связанных с заболеванием в этом отделе коленного сустава, которые отличаются от тех, которые связаны с OA ТФС. Заключение. Пателлофеморальный остеоартрит - важная подгруппа остеоартрита коленного сустава. Вмешательства, такие как фиксация коленной чашечки и физиотерапия, могут облегчить болевой синдром у людей с этим состоянием, однако не устраняют патофизиологические причины. Необходима разработка новых методов хирургического вмешательства. Relevance.Osteoarthritis (OA) is an urgent problem of modern medicine, which is confirmed by a steady increase in the incidence, economic costs of treatment and disability of patients. Since the knee joint is three-component, the radiological manifestations of the disease are numerous. The patellofemoral joint (PFJ) is one of the most frequently affected parts. Although PFJ OA is observed frequently, this particular subgroup of diseases is largely unrecognized. Recent studies show that PFJ is not only an important source of OA knee arthritis symptoms, but people suffering from PFJ OA show signs of illness that are different from those observed with OA of the tibiofemoral joint (TFJ) of the femur-femoral joint. This is important for the assessment and treatment of patients with PFJ OA. The purpose of this review is to summarize the evidence that suggests why PFJ OA should be considered as a separate clinical unit and the main methods of treatment using conservative, non-pharmacological approaches to treatment. Search strategy. Literary search of the electronic databases PubMed / Scopus / MEDLINE, covering the last three decades for the keywords: patellofemoral joint, osteoarthritis, tybiofemoral joint,...

1 May 2019 in Journal of Orthopaedic Surgery
Verified
Journal Article
Open access
PDF file
KAKenes Akilzhanov
Kenes Akilzhanov
EZErsin T Zhunusov
Ersin T Zhunusov
KAKanat T Asylkhanov
Kanat T Asylkhanov
SSSovetkhan B Smakov
Sovetkhan B Smakov
MZMarat A Zhanaspayev
Marat A Zhanaspayev
Purpose: The purpose of this study was to assess the impact of developed minimally invasive operation such as the partial lateral facetectomy (PLFE) with patella thickness resection in patients with lateral patellofemoral (PF) osteoarthritis on short-term clinical and radiographic outcomes. Methods: This is a prospective study of 27 knees in 27 patients (18 females and 9 males, mean aged at surgery 59.1-year old) whom a PLFE with patella thickness resection using developed minimally invasive method was performed. Data of preoperative and postoperative questionnaires, physical examinations, and radiographs were analyzed. The minimum follow-up was 12 months (mean, 24.1 months; range, 12–36 months). Results: The subjective outcomes included the anterior pain relief assessed by scores using the Western Ontario and McMaster Universities Arthritis Index score (scores improved considerably by 2.34 points with respect to pain and by 1.63 points with respect to function), visual analog scale, and Knee Society Score (that improved in 78% of the knees). The majority of these patients experienced improvement in their PF symptoms. The PF index decreased considerably after surgery. The mean patellar width and thickness were decreased after surgery, maintaining a width/thickness ratio of 1.8:1.0 after surgery. Conclusion: PLFE with patella thickness resection aiming to decrease the high pressure in the lateral facet and improving congruence of the patella confirmed frequent pain relief. This surgical procedure is minimally invasive, relatively simple, and effective in selected patients and can be a valid early alternative to more complex operations. Level of Evidence: Level IV Therapeutic study.

8 April 2022 in Наука и здравоохранение
Verified
Journal Article
Open access
НРНи Р.
Ни Р.
DSDariga S Smailova
Dariga S Smailova
ИСИбраев С.е.
Ибраев С.е.
KAKenes Akilzhanov
Kenes Akilzhanov
ЕАЕлисинова А.м.
Елисинова А.м.
Altyn M AringazinaAltyn M Aringazina
Altyn M Aringazina
Актуальность. Травматизм имеет большую социально-экономическую значимость, поскольку приводит к высокому уровню нетрудоспособности и медико-социальным последствиям: инвалидности и смертности. Ежегодно во всем мире от травм умирает более 5 миллионов человек. Из насчитывающихся сейчас в мире 300 млн. инвалидов значительную часть составляют жертвы дорожно-транспортных происшествий. Цель: изучение смертности от несчастных случаев, травм и отравлений в Республике Казахстан. Материалы и методы. Проведен сравнительный ретроспективный анализ смертности от несчастных случаев, травм и отравлений в разрезе регионов Республике Казахстан за 2010-2020 годы по данным статистических сборников "Здоровье населения Республики Казахстан и деятельность организаций здравоохранения», в том числе Мединформ. Результаты исследования. За последние 10 лет по Республике Казахстан в динамике отмечается значительное снижение смертности от несчастных случаев, травм и отравлений. Наблюдается высокая смертность в 2004-2006 годах, варьируя в пределах 148-150,2 на 100 тыс.населения. В 2019 году среднереспубликанский показатель смертности от несчастных случаев, травм и отравлений составил 65,35 на 100 тыс.населения. Наблюдается высокий показатель смертности в Восточно-Казахстанской (108,66) и Северо-Казахстанской (107,14) областях . Самая низкая смертность зарегистрирована в г.Нур-Султан (38,02) и Кызылординской области (38,55). Заключение. Таким образом, в Казахстане в динамике отмечается снижение смертности от несчастных случаев, травм и отравлений. Несмотря на снижение смертности в регионах Северного Казахстана отмечается высокая смертность от несчастных случаев, травм и отравлений в данной части страны сравнительно с Южным и Западным Казахстаном. Background. Injury has a great socio-economic importance, since it leads to a high level of disability and medical and social consequences: disability and mortality. More than 5 million people die from injuries worldwide every year. Of the 300 million people with disabilities in the world today, a significant proportion are victims of road traffic accidents. The aim: is to study mortality from accidents, injuries and poisoning in the Republic of Kazakhstan. Materials and methods. A comparative retrospective analysis of mortality from accidents, injuries and poisoning in the context of the regions of the Republic of Kazakhstan for 2010-2020 was carried out according to the statistical collections "Health of the population of the Republic of Kazakhstan and the activities of healthcare organizations", including Medinform. Results. Over the past 10 years, a significant decrease in mortality from accidents, injuries and poisoning has been observed in the dynamics of the Republic of Kazakhstan. There is a high mortality rate in 2004-2006, varying in the range of 148-150.2 per 100 thousand population. In 2019, the national average mortality rate from accidents, injuries and poisoning was 65.35 per 100 thousand population. There is a high mortality rate in the East Kazakhstan (108.66) and North Kazakhstan (107.14) regions. The lowest mortality rate was recorded in the city of Nur-Sultan (38.02) and the Kyzylorda region (38.55). Conclusion. Thus, in Kazakhstan, there is a decrease in mortality from accidents, injuries and poisoning in dynamics. Despite the decrease in mortality in the regions of northern Kazakhstan, there is a high mortality rate from accidents, injuries and poisoning in this part of the country compared to southern and western Kazakhstan. Зерттеудің өзектілігі. Жарақаттанудың үлкен әлеуметтік-экономикалық маңызы бар, өйткені ол еңбекке қабілетсіздік пен медициналық-әлеуметтік салдардың жоғары деңгейіне әкеледі: мүгедектік пен өлім. Жыл сайын әлемде 5 миллионнан астам адам жарақаттан көз жұмады. Қазіргі таңда әлемдегі 300 млн. мүгедектің басым бөлігін жол-көлік оқиғаларының құрбандары құрайды. Мақсаты. Қазақстан Республикасында жазатайым оқиғалардан, жарақаттардан және уланудан болатын өлім-жітімді зерделеу болып табылады. Материалдары мен әдістері. "Қазақстан Республикасы халқының денсаулығы және...